The drug’s accelerated approval was based on the intermediate endpoint of improvement in knee extensor muscle strength. The FDA is requiring Stealth to conduct a post-approval randomized, double-blind ...
"The idea is that any provider all over the world potentially participates in a clinical trial," Oracle' Seema Verma said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback